Key Points
- Insider sale: Mark Hopman sold 834 shares at $12.36 on March 2 for $10,308, trimming his stake by 0.59%; multiple other executives (including the CFO) also sold in early March, fueling concern about coordinated insider exits.
- Shares and fundamentals: BBNX shares fell about 7.6% and opened at $11.57; the company has a $513.5M market cap, a negative P/E and high volatility (1‑year range $8.89–$32.71), and while it beat EPS estimates ($-0.30 vs. -0.42) revenue was $32.12M and net margin remained deeply negative (-73%).
- Analyst and institutional view: The stock carries a "Moderate Buy" consensus with a $23.20 average price target amid mixed analyst ratings, and recent new stakes were added by institutions including Goldman Sachs and Woodline Partners.
Beta Bionics, Inc. (NASDAQ:BBNX - Get Free Report) insider Mark Hopman sold 834 shares of the business's stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $12.36, for a total transaction of $10,308.24. Following the completion of the sale, the insider directly owned 139,486 shares of the company's stock, valued at $1,724,046.96. This represents a 0.59% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
Beta Bionics Trading Down 7.6%
Shares of BBNX stock opened at $11.57 on Wednesday. The stock has a market cap of $513.48 million, a P/E ratio of -5.93 and a beta of 5.60. Beta Bionics, Inc. has a 1 year low of $8.89 and a 1 year high of $32.71. The stock has a 50 day simple moving average of $18.74 and a 200 day simple moving average of $22.43.
Beta Bionics (NASDAQ:BBNX - Get Free Report) last issued its quarterly earnings results on Tuesday, February 17th. The company reported ($0.30) EPS for the quarter, topping analysts' consensus estimates of ($0.42) by $0.12. The company had revenue of $32.12 million for the quarter. Beta Bionics had a negative return on equity of 20.29% and a negative net margin of 73.02%.
Wall Street Analysts Forecast Growth
Several research analysts have commented on the stock. TD Cowen started coverage on shares of Beta Bionics in a research report on Monday, January 26th. They set a "hold" rating and a $17.00 price objective for the company. UBS Group upgraded Beta Bionics to a "strong-buy" rating in a research report on Monday, February 9th. The Goldman Sachs Group reiterated a "buy" rating and issued a $25.00 target price on shares of Beta Bionics in a research report on Thursday, January 15th. Robert W. Baird dropped their target price on shares of Beta Bionics from $28.00 to $14.00 and set a "neutral" rating for the company in a report on Wednesday, February 18th. Finally, Truist Financial decreased their price target on shares of Beta Bionics from $37.00 to $25.00 and set a "buy" rating on the stock in a report on Monday, February 2nd. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $23.20.
Read Our Latest Research Report on BBNX
Institutional Inflows and Outflows
A number of large investors have recently added to or reduced their stakes in the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in Beta Bionics during the 1st quarter worth approximately $95,000. Goldman Sachs Group Inc. bought a new stake in shares of Beta Bionics in the first quarter worth $715,000. Woodline Partners LP acquired a new stake in Beta Bionics in the first quarter valued at $1,530,000. Strs Ohio acquired a new stake in Beta Bionics in the first quarter valued at $29,000. Finally, Rhumbline Advisers bought a new position in Beta Bionics during the 1st quarter worth $158,000.
More Beta Bionics News
Here are the key news stories impacting Beta Bionics this week:
- Neutral Sentiment: Short‑interest data appears unreliable or reporting‑error driven (entries show “0 shares”/NaN and 0.0 days to cover), so there’s no clear signal from short sellers in these reports — treat short‑interest changes as inconclusive for now.
- Negative Sentiment: Multiple insiders sold shares in early March (CFO Stephen Feider sold 1,428 shares at ~$12.36; other executives also sold small blocks), prompting the narrative of a wave of executive exits that can pressure the stock. These trades were disclosed in SEC Form 4 filings and covered in a TipRanks piece highlighting the coordinated sales. Beta Bionics Insiders Quietly Cash Out CFO Form 4
- Negative Sentiment: A securities‑litigation firm (Faruqi & Faruqi, LLP) issued a shareholder reminder/investigation notice encouraging investors who suffered losses to contact them — this increases legal and reputational risk and can weigh on sentiment and share price until resolved. Faruqi & Faruqi Shareholder Reminder
About Beta Bionics
(
Get Free Report)
Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company's flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.
At the core of Beta Bionics' offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual‐hormone modes.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
